Evidence map›Paper›PMID 34085509›Full record

ArticleCanadian journal of surgery. Journal canadien de chirurgie2021

Identification of hypercoagulability with thrombelastography in patients with hip fracture receiving thromboprophylaxis.

Daniel You, Leslie Skeith, Robert Korley, Paul Cantle, Adrienne Lee, Paul McBeth, Braedon McDonald, Richard Buckley, Paul Duffy, C. Ryan Martin and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Canadian journal of surgery. Journal canadien de chirurgie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Post hip fracture orthogeriatric care-a Canadian position paper addressing challenges in care and strategies to meet quality indicators.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Daniel YouFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Leslie SkeithFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Robert KorleyFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Paul CantleFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Adrienne LeeFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Paul McBethFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Braedon McDonaldFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Richard BuckleyFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Paul DuffyFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
C. Ryan MartinFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).ORCID `
Andrea SooFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
Prism SchneiderFrom the Division of Orthopaedic Surgery, University of Calgary, Calgary, Alta. (You, Korley, Buckley, Duffy, Martin, Schneider); the Division of Hematology & Hematological Malignancies, University of Calgary, Calgary, Alta. (Skeith, Lee); the Section of General Surgery, University of Calgary, Calgary, Alta. (Cantle, McBeth); the Section of Vascular Surgery, University of Calgary, Calgary, Alta. (Cantle); and the Department of Critical Care, University of Calgary, Calgary, Alta. (McBeth, McDonald, Soo).
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Venous thromboembolism (VTE) is the second most common complication after hip fracture surgery. We used thrombelastography (TEG), a whole-blood, point-of-care test that can provide an overview of the clotting process, to determine the duration of hypercoagulability after hip fracture surgery. Methods: In this prospective study, consecutive patients aged 51 years or more with hip fractures (trochanteric region or neck) amenable to surgical treatment who presented to the emergency department were eligible for enrolment. Thrombelastography, including calculation of the coagulation index (CI) (combination of 4 TEG parameters for an overall assessment of coagulation) was performed daily from admission until 5 days postoperatively, and at 2 and 6 weeks postoperatively. All patients received 28 days of thromboprophylaxis. We used single-sample t tests to compare mean maximal amplitude (MA) values (a measure of clot strength) to the hypercoagulable threshold of greater than 65 mm, a predictor of in-hospital VTE. Results: Of the 35 patients enrolled, 11 (31%) were hypercoagulable on admission based on an MA value greater than 65 mm, and 29 (83%) were hypercoagulable based on a CI value greater than 3.0; the corresponding values at 6 weeks were 23 (66%) and 34 (97%). All patients had an MA value greater than 65 mm at 2 weeks. Patients demonstrated normal coagulation on admission (mean MA value 62.2 mm [standard deviation (SD) 6.3 mm], p = 0.01) but became significantly hypercoagulable at 2 weeks (mean 71.6 mm [SD 2.6 mm], p < 0.001). There was a trend toward persistent hypercoagulability at 6 weeks (mean MA value 66.2 mm [SD 3.8 mm], p = 0.06). Conclusion: More than 50% of patients remained hypercoagulable 6 weeks after fracture despite thromboprophylaxis. Thrombelastography MA thresholds or a change in MA over time may help predict VTE risk; however, further study is needed.

Indexed as

ThrombelastographyAged, 80 and overAnticoagulantsBlood Coagulation TestsFemaleHip FracturesHumansMaleProspective StudiesThrombophiliaVenous ThromboembolismAnticoagulants

Identifiers

PMID34085509
PMCPMC8327983
OpenAlexW3164024970

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.